Quantcast

Latest Docetaxel Stories

2013-01-11 02:20:01

Tokyo, Jan 11, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today the preliminary results of its global Phase III study (Study FAR 131, MORAb-003-004) of farletuzumab (MORAb-003), an investigational compound under development at its U.S. subsidiary, Morphotek, Inc., in patients with platinum-sensitive epithelial ovarian cancer in first relapse.The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative study of 1,100 patients with...

2012-10-01 12:26:56

Phase III data reported at ESMO 2012 New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Phase III, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy The first phase III trial to address the need for second-line treatments in esophageal cancer shows that...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'